This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can Moderna's (MRNA) Launches Reduce COVID Sales Dependency?
by Zacks Equity Research
With COVID-19 vaccine sales declining, Moderna (MRNA) is accelerating the development of its non-COVID pipeline. It is gearing up for potential product launches over the next five years.
Merck (MRK) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Curious about Pfizer (PFE) Q4 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Pfizer (PFE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.
Pfizer (PFE) to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
Pfizer's (PFE) revenues are expected to have declined in the fourth quarter of 2023 due to a steep decline in sales of its COVID-19 products on lower demand.
Earnings Preview: Pfizer (PFE) Q4 Earnings Expected to Decline
by Zacks Equity Research
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $28.31, marking a +0.11% move from the previous day.
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
by Zacks Equity Research
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pfizer (PFE) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
In the closing of the recent trading day, Pfizer (PFE) stood at $28.32, denoting a -1.32% change from the preceding trading day.
Pharma Stock Roundup: MRK to Buy Harpoon, JNJ to Acquire Ambrx Biopharma & More
by Kinjel Shah
Merck (MRK) offers to acquire Harpoon for $680 million. J&J (JNJ) is set to acquire Ambrx Biopharma for approximately $2.0 billion
Here's Why Pfizer (PFE) Fell More Than Broader Market
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $29.40, moving -0.61% from the previous trading session.
Ambrx (AMAM) Skyrockets 102% on $2B Buyout Offer From J&J
by Zacks Equity Research
J&J (JNJ) is set to acquire Ambrx Biopharma (AMAM) in an all-cash transaction for $2.0 billion. The transaction will likely close in first-half 2024.
MercadoLibre and Pfizer have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
MercadoLibre and Pfizer are part of the Zacks Bull and Bear of the Day article.
Bear of the Day: Pfizer (PFE)
by Derek Lewis
Negative earnings estimate revisions from analysts and weakening sales post-pandemic paint a challenging picture for the company's shares in the near term.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer (PFE) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $29.73, making no change from the previous trading session.
Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
In the most recent trading session, Pfizer (PFE) closed at $28.61, indicating a +0.7% shift from the previous trading day.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Pharma Stock Roundup: FDA Nod to AZN's Eplontersen, CRL to MRK's Cough Candidate
by Kinjel Shah
FDA approves AstraZeneca (AZN) and Ionis' (IONS) Wainua (eplontersen) for ATTRv-PN and gives CRL to Merck's chronic cough candidate, gefapixant.
FDA Accepts Merck's (MRK) BLA for 21-Valent Pneumococcal Jab
by Zacks Equity Research
The FDA grants priority review to Merck's (MRK) filing seeking approval for its 21-valent pneumococcal conjugate vaccine in adults. A final decision is expected in June 2024.
Pfizer (PFE) Stock Rises on FDA Nod for Expanded Use of Padcev
by Zacks Equity Research
The FDA approves Pfizer's (PFE) Padcev in combination with Merck's (MRK) Keytruda for adult patients with advanced bladder cancer. Stock rises 1.6%.
Pfizer (PFE) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
The latest trading day saw Pfizer (PFE) settling at $27.06, representing a +1.61% change from its previous close.
Pharma Stock Roundup: PFE Issues Weak 2024 View, AZN to Buy Icosavax & More
by Kinjel Shah
Pfizer (PFE) issues a disappointing outlook for 2024. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax.
Company News for Dec 14, 2023
by Zacks Equity Research
Companies in The News Are: ABM,PFE,HD,GS
Pfizer (PFE) Stock Sinks on Weak 2024 View as COVID Sales Fall
by Zacks Equity Research
Pfizer's (PFE) shares decline almost 7% in response to the muted guidance for 2024. Revenues are expected to be in the range of $58.5 to $61.5 billion, while adjusted EPS is expected in the range of $2.05 to $2.25.
The Zacks Analyst Blog Highlights The Home Depot, Advanced Micro Devices, Pfizer, The Cigna Group and Live Nation Entertainment
by Zacks Equity Research
The Home Depot, Advanced Micro Devices, Pfizer, The Cigna Group and Live Nation Entertainment are part of the Zacks top Analyst Blog.